Compare Crocs, Inc. (CROX) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crocs, Inc. vs Nuwellis Inc — how do they compare? Crocs, Inc. trades at $131.6 (market cap $6.63B), while Nuwellis Inc trades at $1.5 (market cap $522.76K). The key difference: Crocs, Inc. is far larger — about 12682.7× Nuwellis Inc's market cap, and Crocs, Inc. is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| CROX | NUWE | |
|---|---|---|
Market Cap | $6.63B | $522.76K |
Sector | Consumer Staples | Technology |
52-Week High | $141.19 | $220.50 |
52-Week Low | $73.39 | $1.42 |
Enterprise Value | $8.14B | -$1.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $136.62, up 1.82% with strong technical momentum and bullish moving averages. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $4.55 exceeding expectations. Despite a net loss in 2025 due to tax impacts, profitability metrics remain robust with 57.47% gross margins and 42.3% ROE. Recent news highlights tax strategy scrutiny but also strong DTC growth and raised 2026 guidance.
The stock presents value with a 12.12 P/E ratio below industry averages, supported by analyst consensus of $140.43 price target. Key risks include HEYDUDE brand weakness, tariff pressures, and ongoing tax scrutiny. Upside potential exists from international expansion and direct-to-consumer growth, though near-term volatility may persist around earnings.
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
